A polypeptide exhibiting diabetogenic and anti-insulin properties has been isolated from the urine of 33 of the 35 proteinuric diabetic patients. This material could not be found in the urine of 34 normal subjects and 32 diabetic patients without proteinuria. It was, however, detected chemically in one of seven nondiabetic patients with proteinuria, but the amount present was insufficient for biological testing. I N 1963 WE REPORTED that the urine of patients with lipoatrophic diabetes contains a diabetogenic po1ypeptide.l This has recently been confumed by others.2 We demonstrated that the peptide was capable of impairing glucose tolerance and of inducing insulin resistance when administered either to dogs or humans. The present study was designed to explore the possibility that a similar substance might be found in the urine of diabetic patients without lipodystrophy since a chance observation had disclosed its presence in an obese, maturity-onset diabetic. l Freshly collected urine samples from 67 diabetic patients and 34 healthy subjects have been studied. The diabetogenic peptide was found in the urine of 33 of 35 diabetics with proteinuria but it was absent in all of 32 diabetics without proteinuria, as well as in the normal subjects. Seven additional subjects with proteinuria but without diabetes were studied. One of them exhibited a similar urinary material.
Maintenance and preparation of dogs for glucose and insulin tolerance tests have been previously described.627 In the present studies, two well-trained dogs were employed. However, because of the scarcity of the purified material, most of the tests were done on a small animal (Dog P, 7.4 Kg.). The assay procedure consisted of (a) a control glucose tolerance test done on day 1, and (b) an injection of the substance 10 hours before the second glucose tolerance test which was done on day 2. An interval of at least 13 days elapsed before the procedure was repeated in the same animal with the isolated peptide from another patient.
Blood glucose was measured by the Somogyi-Nelson procedure.4 Disc electrophoresis was performed in a Model 6 apparatus* with a single bath assembly. The power source was Model 200." Analyses were carried out according to the procedure of Ornstein and Davis.5 Electrophoresis was carried out at room temperature at a current of 4 ma per tube for 30 minutes. Polypeptide samples used were 60-100 pg. per tube. The buffer was of pH 8.3. Destaining was performed at a current of 12.5 ma per tube for 60 minutes.
RESULTS
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Elemental analysis of the diabetogenic polypeptide from patient W.W. shows the following: C 48.14 per cent, H 6.89 per cent, N 14.68 per cent, and S 1.49 per cent. These values are almost the same as those obtained upon the peptide isolated from the urine of patients with lipoatrophic diabetes.6 Figure 4 shows the polyacrylamide gel electrophoretic patterns of fraction 1 from a lipoatrophic diabetic (pattern 3) and from 3 diabetics with proteinuria (patterns 4, 5 and 6). For comparison (Fig. 5 ) disc electrophoresis was also performed on fraction 1 isolated from bovine (pattern 7) and human (pattern 8) pituitary glands. Further purification of these fractions by Sephadex column chromatography is now in progress.
DISCUSSION
Since our report1 on the isolation of a diabetogenic polypeptide from the urine of patients with lipoatrophic diabetes and the chance observation that it was present in a proteinuric maturity-onset diabetic, we have been seeking to find the material in other diabetic patients. The significance of the associated proteinuria was not appreciated initially. It is now apparent that the peptide was present in the urine of 33 of the 35 diabetics with proteinuria but was present neither in 32 nonproteinuric diabetics nor in 34 healthy subjects. In 1 of 7 nondiabetics with proteinuria, a small amount of material which precipitated at pH 4.1 was found but it was insufficient to test for biological activity. When the material is present in proteinuric urine, it is not related quantitatively to the amount of protein excreted. Nineteen (58%) of the 33 patients excreting this peptide had detectable diabetic retinopathy of various grades and it is evident that all had some form of nephropathy. The observation that the diabetogenic peptide disappeared from the urine following hypophysectomy in the one such case in which it was studied, together with our ability to isolate a similar material from the adenohypophysis of beef, sheep, and swine, suggests that it originates in the pituitary gland. It is tempting to suggest that this material might somehow be involved in the microangiopathy of diabetes mellitus. In recent studies with frozen human pituitary glands, we have succeeded in isolating a polypeptide (isoelectric point approximately pH 4.1) which closely resembles the substance isolated from the urine of patients with proteinuria and diabetes mellitus. These studies will be detailed in another communication.
